KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$12.77 USD
-0.28 (-2.15%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $12.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KALV 12.77 -0.28(-2.15%)
Will KALV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KALV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALV
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KALV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV ...
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)
KalVista (KALV) Advances in Europe with Sebetralstat Approval
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista (KALV) Awaits EU Approval for Sebetralstat for Hereditary Angioedema | KALV Stock News